Trial intelligence / Profile preview

Regorafenib vs fruquintinib as third-line therapy for colorectal cancer

ChiCTR2000040543Phase 3Not yet recruiting

Sponsor

Maoming People's Hospital

Start

Dec 2020

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1